Paradigm Biopharmaceuticals Limited Stock
Stocks
PAR
AU000000PAR5
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
02:10:26 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.2450 AUD | -2.00% |
|
+2.08% | -27.94% |
| 09-14 | Paradigm Biopharmaceuticals Names Chief Medical Officer | MT |
| 09-10 | Paradigm Biopharmaceuticals Draws Down Final $2 Million of Tranche 4 From Convertible Note Facility; Shares Down 13% | MT |
| Market Cap | 147M 105M 91.16M 85.8M 78.11M 147M 10.01B 1.03B 396M 5.1B 393M 384M 16.45B | P/E 2027 * |
-2.95x | P/E 2028 * | 1.35x |
|---|---|---|---|---|---|
| Enterprise Value | 135M 95.99M 83.71M 78.78M 71.73M 135M 9.2B 944M 364M 4.69B 360M 353M 15.11B | EV / Sales 2027 * |
-
| EV / Sales 2028 * | -0.35x |
| Free-Float |
96.73% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| PAR | Delayed | |
OTC Markets
| PBIGF | Delayed | |
|
Deutsche Boerse AG
| P86 | Delayed | |
|
Börse Stuttgart
| P86 | Delayed | |
|
Tradegate
| P86 | Real-time | |
|
Boerse Muenchen
| P86 | Real-time |
| 1 day | -2.00% | ||
| 1 week | +2.08% | ||
| Current month | +8.89% | ||
| 1 month | +40.00% | ||
| 3 months | +44.12% | ||
| 6 months | -9.26% | ||
| Current year | -27.94% |
| 1 week | 0.24 |  | 0.26 |
| 1 month | 0.18 | | 0.3 |
| Current year | 0.14 | | 0.37 |
| 1 year | 0.14 | | 0.47 |
| 3 years | 0.14 | | 0.78 |
| 5 years | 0.14 | | 2.69 |
| 10 years | 0.14 | | 4.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Rennie
CEO | Chief Executive Officer | - | 2022-11-21 |
| Director of Finance/CFO | - | 2023-03-02 | |
| Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Rennie
CHM | Chairman | - | - |
Amos Meltzer
BRD | Director/Board Member | 60 | 2020-12-08 |
Matthew Fry
BRD | Director/Board Member | - | 2024-03-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/2/26 | Buy | Chief Executive Officer | 176,470 | 0.0336% | ||
| 6/2/26 | Buy | Chief Executive Officer | 176,470 | 0.0336% | ||
| 6/2/26 | Buy | Chief Executive Officer | 176,470 | 0.0336% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.00% | +2.08% | -16.95% | -60.48% | 104M | |
| +0.59% | +3.31% | +1.03% | +24.53% | 46.28B | |
| +1.30% | +3.10% | +44.15% | +31.38% | 43.85B | |
| +0.95% | -5.40% | +342.72% | +548.37% | 40.93B | |
| +4.23% | +5.53% | +9.35% | +89.62% | 39.89B | |
| +1.11% | +1.80% | +11.52% | +43.15% | 29.5B | |
| +1.94% | +6.24% | +25.19% | +145.07% | 17.09B | |
| +0.37% | -9.84% | - | - | 15.55B | |
| +2.12% | +10.41% | +24.78% | +39.05% | 15.22B | |
| +0.24% | +32.23% | -11.57% | - | 14.05B | |
| Average | +0.97% | +3.78% | +47.80% | +107.59% | 26.25B | |
| Weighted average by Cap. | +1.38% | +2.08% | +70.34% | +141.15% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | - | 322M 229M 200M 188M 171M 322M 21.96B 2.25B 869M 11.19B 861M 842M 36.07B |
| Net income | -44.8M -31.9M -27.82M -26.18M -23.84M -44.76M -3.06B -314M -121M -1.56B -120M -117M -5.02B | 99.5M 70.85M 61.79M 58.15M 52.94M 99.41M 6.79B 697M 268M 3.46B 266M 260M 11.15B |
| Net Debt | -12M -8.54M -7.45M -7.01M -6.39M -11.99M -819M -84.03M -32.38M -417M -32.09M -31.38M -1.34B | -260M -185M -161M -152M -138M -260M -17.74B -1.82B -702M -9.04B -695M -680M -29.14B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | A$0.2450 | -2.00% | 3,137,503 |
| 26-09-17 | A$0.2500 | 0.00% | 1,882,510 |
| 26-09-16 | A$0.2500 | 0.00% | 1,647,165 |
| 26-09-15 | A$0.2500 | +4.17% | 1,748,329 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- PAR Stock
Select your edition
All financial news and data tailored to specific country editions
